Risk factors for developing severe COVID-19 in China: an analysis of disease surveillance data

被引:32
作者
Geng, Meng-Jie [1 ]
Wang, Li-Ping [1 ]
Ren, Xiang [1 ]
Yu, Jian-Xing [2 ]
Chang, Zhao-Rui [1 ]
Zheng, Can-Jun [1 ]
An, Zhi-Jie [3 ]
Li, Yu [1 ]
Yang, Xiao-Kun [1 ]
Zhao, Hong-Ting [1 ]
Li, Zhong-Jie [1 ]
He, Guang-Xue [4 ]
Feng, Zi-Jian [1 ]
机构
[1] Chinese Ctr Dis Control & Prevent, Div Infect Dis, Beijing, Peoples R China
[2] Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, Beijing, Peoples R China
[3] Chinese Ctr Dis Control & Prevent, Natl Immunizat Program, Beijing, Peoples R China
[4] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
COVID-19; Severe case; Non-severe case; Risk factor;
D O I
10.1186/s40249-021-00820-9
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: COVID-19 has posed an enormous threat to public health around the world. Some severe and critical cases have bad prognoses and high case fatality rates, unraveling risk factors for severe COVID-19 are of significance for predicting and preventing illness progression, and reducing case fatality rates. Our study focused on analyzing characteristics of COVID-19 cases and exploring risk factors for developing severe COVID-19. Methods: The data for this study was disease surveillance data on symptomatic cases of COVID-19 reported from 30 provinces in China between January 19 and March 9, 2020, which included demographics, dates of symptom onset, clinical manifestations at the time of diagnosis, laboratory findings, radiographic findings, underlying disease history, and exposure history. We grouped mild and moderate cases together as non-severe cases and categorized severe and critical cases together as severe cases. We compared characteristics of severe cases and non-severe cases of COVID-19 and explored risk factors for severity. Results: The total number of cases were 12 647 with age from less than 1 year old to 99 years old. The severe cases were 1662 (13.1%), the median age of severe cases was 57 years [Inter-quartile range(IQR): 46-68] and the median age of non-severe cases was 43 years (IQR: 32-54). The risk factors for severe COVID-19 were being male [adjusted odds ratio (aOR) = 1.3, 95% CI: 1.2-1.5]; fever (aOR = 2.3, 95% CI: 2.0-2.7), cough (aOR = 1.4, 95% CI: 1.2-1.6), fatigue (aOR = 1.3, 95% CI: 1.2-1.5), and chronic kidney disease (aOR = 2.5, 95% CI: 1.4-4.6), hypertension (aOR = 1.5, 95% CI: 1.2-1.8) and diabetes (aOR = 1.96, 95% CI: 1.6-2.4). With the increase of age, risk for the severity was gradually higher [20-39 years (aOR = 3.9, 95% CI: 1.8-8.4), 40-59 years (aOR = 7.6, 95% CI: 3.6-16.3), >= 60 years (aOR = 20.4, 95% CI: 9.5-43.7)], and longer time from symtem onset to diagnosis [3-5 days (aOR = 1.4, 95% CI: 1.2-1.7), 6-8 days (aOR = 1.8, 95% CI: 1.5-2.1), >= 9 days(aOR = 1.9, 95% CI: 1.6-2.3)]. Conclusions: Our study showed the risk factors for developing severe COVID-19 with large sample size, which included being male, older age, fever, cough, fatigue, delayed diagnosis, hypertension, diabetes, chronic kidney diasease, early case identification and prompt medical care. Based on these factors, the severity of COVID-19 cases can be predicted. So cases with these risk factors should be paid more attention to prevent severity.
引用
收藏
页数:10
相关论文
共 53 条
[1]  
[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
[2]   The interplay between COVID 19 and non-communicable diseases [J].
Chaturvedi, Seemant ;
Gorelick, Philip .
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2020, 29 (09)
[3]   The characteristics and outcomes of 681 severe cases with COVID-19 in China [J].
Chen, Fang-fang ;
Zhong, Ming ;
Liu, Ya ;
Zhang, Yi ;
Zhang, Kai ;
Su, De-zhen ;
Meng, Xiao ;
Zhang, Yun .
JOURNAL OF CRITICAL CARE, 2020, 60 :32-37
[4]   Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J].
Chen, Nanshan ;
Zhou, Min ;
Dong, Xuan ;
Qu, Jieming ;
Gong, Fengyun ;
Han, Yang ;
Qiu, Yang ;
Wang, Jingli ;
Liu, Ying ;
Wei, Yuan ;
Xia, Jia'an ;
Yu, Ting ;
Zhang, Xinxin ;
Zhang, Li .
LANCET, 2020, 395 (10223) :507-513
[5]  
Chen W, 2004, DIAGNOSTICS, V6th, P271
[6]  
Chen Xi, 2020, Chongqing Medicine, V49, P2802
[7]  
China NHCotPsRo, GUID DIAGN TREATM PA, V8
[8]  
China NHCotPsRo, GUIDELINES DIAGNOSIS
[9]  
China NHCotPsRo, PROTOCOL PREVENTION, V4
[10]  
China NHCotPsRo, NOT NAT HLTH COMM PE